within Pharmacolibrary.Drugs.ATC.S;

model S01KA51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.015 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Hyaluronic acid, in combination with other agents, is used primarily in ophthalmology for intraocular procedures, such as cataract extraction, corneal transplantation, and glaucoma filtration surgery. It is a viscoelastic substance providing lubrication and volume replacement in the eye. It is also present in some topical eye preparations for lubrication. It is approved for use in several countries and continues to be used clinically.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for an average adult ophthalmic patient (sex unspecified, age unspecified) receiving intraocular administration of hyaluronic acid combination.</p><h4>References</h4><ol><li><p>Kim, DJ, et al., &amp; Park, CY (2021). Moxifloxacin releasing intraocular implant based on a cross-linked hyaluronic acid membrane. <i>Scientific reports</i> 11(1) 24115–None. DOI:<a href=&quot;https://doi.org/10.1038/s41598-021-03605-0&quot;>10.1038/s41598-021-03605-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34916593/&quot;>https://pubmed.ncbi.nlm.nih.gov/34916593</a></p></li><li><p>Guo, Z, et al., &amp; Li, JL (2024). Injectable nanocomposite hydrogel with cascade drug release for treatment of uveal melanoma. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 376 1086–1099. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2024.11.001&quot;>10.1016/j.jconrel.2024.11.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39500408/&quot;>https://pubmed.ncbi.nlm.nih.gov/39500408</a></p></li><li><p>Brugnera, M, et al., &amp; Herrero-Vanrell, R (2024). Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents. <i>Drug delivery and translational research</i> 14(10) 2804–2822. DOI:<a href=&quot;https://doi.org/10.1007/s13346-024-01584-z&quot;>10.1007/s13346-024-01584-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38602615/&quot;>https://pubmed.ncbi.nlm.nih.gov/38602615</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01KA51;
